5′-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: An adenylation enzyme required for siderophore biosynthesis of the mycobactins

Journal of Medicinal Chemistry

Volumn 50, Issue 24, 2007, Pages 6080-6094

  Qiao, Chunhua ^a   Gupte, Amol ^a   Boshoff, Helena I ^b   Wilson, Daniel J ^a   Bennett, Eric M ^a   Somu, Ravindranadh V ^a   Barry III, Clifton E ^b   Aldrich, Courtney C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' O [(N SALICYL)SULFAMOYL]ADENOSINE; 5' O [N (4 AMINO 2 HYDROXYBENZOYL)SULFAMOYL]ADENOSINE; ADENOSINE DERIVATIVE; ALKYL GROUP; BACTERIAL ENZYME; FLUORINE DERIVATIVE; HETEROCYCLIC COMPOUND; HYDROXYL GROUP; IRON; ISONIAZID; LIGASE; MYCOBACTIN DERIVATIVE; PEPTIDE SYNTHASE; PROTEIN MBTA; SALICYLADENOSINE MONOPHOSPHATE LIGASE; SIDEROPHORE; SULFONAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; 5' O (N (SALICYL)SULFAMOYL)ADENOSINE; 5'-O-(N-(SALICYL)SULFAMOYL)ADENOSINE; ADENOSINE; DRUG DERIVATIVE; MYCOBACTINS; OXAZOLE DERIVATIVE; SALICYL AMP LIGASE, MYCOBACTERIUM TUBERCULOSIS; SALICYL-AMP LIGASE, MYCOBACTERIUM TUBERCULOSIS;

ADENYLATION; ARTICLE; BACTERIAL CELL; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME SPECIFICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MICROBIOLOGICAL EXAMINATION; SYNTHESIS;

ADENOSINE; ANTITUBERCULAR AGENTS; LIGASES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLES; PEPTIDE SYNTHASES; SIDEROPHORES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37849036789     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070905o     Document Type: Article

References (34)

1. World Health Organization. 2005 Fact sheet on tuberculosis, http://www.who.int/mediacentre/factsheets/fs104/en/print.html.
2. Ratledge, C.; Dover, L. G. Iron metabolism in pathogenic bacteria. Annu. Rev. Microbiol. 2000, 54, 881-941.
3. Posey, J. E.; Gherardini, F. C. Lack of a role for iron in the lyme disease pathogen. Science 2000, 288, 1651-1653.
4. Raymond, K. N.; Dertz, E. A.; Kim, S. S. Enterobactin: an archetype for microbial iron transport. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3584-3588.
5. (a) Crosa, J. H.; Walsh, C. T. Genetics and assembly line enzymology of siderophore biosynthesis in bacteria. Microbiol. Mol. Biol. Rev. 2002, 66, 223-249.
6. Vergne, A. F.; Walz, A. J.; Miller, M. J. Iron chelators from mycobacteria (1954-1999) and potential therapeutic applications. Nat. Prod. Rep 2000, 17, 99-116.
7. Snow, G. A. Mycobactins: iron-chelating growth factors from mycobacteria. Bacteriol. Rev. 1970, 34, 99-125.
8. Quadri, L. E. N.; Sello, J.; Keating, T. A.; Weinreb, P. H.; Walsh, C. T. Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. Chem. Biol. 1998, 5, 631-645.
9. Schimmel, P.; Tao, J.; Hill, J. Aminoacyl t-RNA synthetases as targets for new anti-infectives. FASEB J. 1998, 12, 1599-1609.
10. Kim, S.; Lee, S. W.; Choi, E.-C.; Choi, S. Y. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl. Microbiol. Biotechnol. 2003, 61, 278-288.
11. Somu, R. V.; Boshoff, H.; Qiao, C. H.; Bennett, E. M.; Barry, C. E.; Aldrich, C. C. Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J. Med. Chem. 2006, 49, 31-34.
12. Vannada, J.; Bennett, E. M.; Wilson, D. J.; Boshoff, H. I.; Barry, C. E., III; Aldrich, C. C. Design, synthesis, and biological evaluation of β-ketosulfonamide adenylation inhibitors as potential antitubercular agents. Org. Lett. 2006, 8, 4707-4710.
13. Qiao, C.; Wilson, D. J.; Bennett, E. M.; Aldrich, C. C. A mechanism-based aryl carrier protein/thiolation domain affinity probe. J. Am. Chem. Soc. 2007, 129, 6350-6351.
14. Ferreras, J. A.; Ryu, J. S.; Di Lello, F.; Tan, D. S.; Quadri, L. E. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat. Chem. Biol. 2005, 1, 29-32.
15. Somu, R. V.; Wilson, D. J.; Bennett, E. M.; Boshoff, H. I.; Celia, L.; Beck, B. J.; Barry, C. E., III; Aldrich, C. C. Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J. Med. Chem. 2006, 49, 7623-7635.
16. Miethke, M.; Bisseret, P.; Beckering, C. L.; Vignard, D.; Eustache, J.; Marahiel, M. A. Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesis. FEBS J. 2006, 273, 409-419.
17. Pfleger, B. F.; Lee, J. Y.; Somu, R. V.; Aldrich, C. C.; Hanna, P. C.; Sherman, D. H. Characterization and analysis of early enzymes for petrobactin biosynthesis in Bacillus anthracis. Biochemistry 2007, 46, 4147-4157.
18. Castro-Pichel, J.; García-López, M. T.; De las Heras, F. G. A facile synthesis of ascamycin and related analogues. Tetrahedron 1987, 43, 383-389.
19. 13C NMR: 181.4 (C = O, C-1), 40.3 (C-2), 38.8 (C-3). HMBC H-2 (coupled to C-1, C-3), H-3 (coupled to C-1, H-2, and C=O at 160.2 from (morpholino)carbonyl fragment).
20. Vasilevich, N. I.; Sachinvala, N. D.; Maskos, K.; Coy, D. H. Selective conversion of O-succinimidyl carbamates to N-(O-carbamoyl)- succinmonoamides and ureas. Tetrahedron Lett. 2002, 43, 3443-3445.
21. May, J. J.; Kessler, N.; Marahiel, M. A.; Stubbs, M. T. Crystal structure of DhbE, an archetype for aryl acid activating domains of modular nonribosomal peptide synthetases. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12120-12125.
22. Liu, F.; Austin, D. J. A general synthesis of 5′-azido-5′- deoxy-2′,3′-O-isopropylidene nucleosides. J. Org. Chem. 2001, 66, 8643-8645.
23. Yu, M.; Magalhães, M. L. B.; Cook, P. F.; Blanchard, J. S. Bisubstrate inhibition: Theory and application to N-acetyltransferases. Biochemistry 2006, 45, 14788-14794.
24. May, J. J.; Wendrich, T. M.; Marahiel, M. A. The dhb operon of Bacillus subtilis encodes the biosynthetic template for the catecholic siderophore 2,3-dihydroxybenzoate-glycine-threonine trimeric ester bacillibactin. J. Biol. Chem. 2001, 276, 7209-7217.
25. Cendrowski, S.; MacArthur, W.; Hanna, P. Bacillus anthracis requires siderophore biosynthesis for Growth in macrophages and mouse virulence. Mol. Microbiol. 2004, 51, 407-417.
26. Keana, J. F. W.; Cai, S. X. New reagents for photoaffinity-labeling - Synthesis and photolysis of functionalized perfluorophenyl azides. J. Org. Chem. 1990, 55, 3640-3647.
27. Trivedi, O. A.; Arora, P.; Sridharan, V.; Tickoo, R.; Mohanty, D.; Gokhale, R. S. Enzymatic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature 2004, 428, 441-445.
28. Gokhale, R. S.; Saxena, P.; Chopra, T.; Mohanty, D. Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids. Nat. Prod. Rep. 2007, 24, 267-277.
29. Tse, B.; Kishi, Y. Conformationally rigid tricyclic tripods: Synthesis and application to preparation of enterobactin analogs. J. Org. Chem. 1994, 59, 7807-7814.
30. Linne, U.; Marahiel, M. A. Reactions catalyzed by mature and recombinant nonribosomal peptide synthetases. Methods Enzymol. 2004, 388, 293-315.
31. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery; Wiley: Hoboken, NJ, 2005.
32. (a) Hu, J.; Miller, M. J. Total synthesis of mycobactin S, a siderophore growth promoter of Mycobacterium smegmatis, and determination of its growth inhibitory activity against Mycobacterium tuberculosis. J. Am. Chem. Soc. 1997, 119, 3462-3468.
33. (b) Xu, Y.; Miller, M. J. Total synthesis of mycobactin analogues as potent antimycobacterial agents using a minimal protecting group strategy. J. Org. Chem. 1998, 63, 4314-4322.
34. (c) Walz, A. J.; Mollmann, U.; Miller, M. J. Synthesis and studies of catechol-containing mycobactin S and T analogs. Org. Biomol. Chem. 2007, 5, 1621-1628.